Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-114 in adults with moderate to severe major depressive disorder
ACTRN12619000575134Phase 2Completed
- Sponsor
- Praxis Precision Medicines
- Start
- May 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PRAX-114 in major depressive disorder (MDD) (3 arms), sponsored by Praxis Precision Medicines. Primary endpoints: Safety and tolerability of PRAX-114 and Pharmacokinetics of PRAX-114. Started May 2019; status: completed.
02
Drugs
PRAX-114
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12619000575134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000575134.